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Abstract
Aims: Amniotic infection (AI) and preeclampsia (PE),
which are commonly the reason for prematurity, inflict
stress of different duration on immature fetuses. Whether
chronic stress, as reflected by intrauterine growth retar-
dation, influences the level of 17-OH progesterone
(17-OHP), was not previously examined.
Methods: We analyzed 17-OHP and TSH levels during
neonatal screenings in the first hours of life of 90 pre-
mature infants born between 25 and 33 weeks of ges-
tation in infants with AI (ns37) or with PE (ns53). Control
of acute stress parameters was derived from umbilical
arterial cord blood pH and base excess (BE).
Results: Mean 17-OHP levels of infants born to mothers
with PE were 85.7 nmol/L compared to 54.6 nmol/L
(P-0.001) in AI infants. 17-OHP was even higher when
intrauterine growth restriction was present (99.8 nmol/L).
Antenatal steroids and mode of delivery did not signifi-
cantly affect 17-OHP levels.
Conclusions: Stress of relatively long duration, as in cas-
es of PE, leads to a significant increase of 17-OHP level
in preterm infants. The postnatal 17-OHP level may be
considered as a measure for severity of intrauterine
stress and might be used as an individualized indicator
for earlier intensive care.
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Introduction
In 1992, Switzerland introduced a screening test for con-
genital adrenal hyperplasia based on the 17-hydroxypro-
gesterone (17-OHP) level in neonatal blood. Physiological
17-OHP values for the days and weeks after birth are
thus well defined w11, 18, 21, 28x. Initial levels in preterm
infants are much higher than in term infants, but this does
not necessarily indicate congenital adrenal hyperplasia.
Rather, it appears that intrauterine stress stimulates fetal
steroid synthesis by activating the hypothalamic-pitui-
tary-adrenocortical axis. Elevated postnatal cortisol lev-
els are characteristic of infants born prematurely after
amniotic infection (AI) or preeclampsia (PE) w2, 6, 9, 10,
12, 22x. As a precursor of the cortisol pathway 17-OHP
could thus serve as a marker of intrauterine stress.
In developed countries the incidence of preterm birth
varies between 5 and 10% w32x and divides into two large
and relatively homogeneous groups. AI due to the access
of bacteria to the amniotic fluid and, by extension to the
placenta, causes relatively brief fetal stress because in
most cases premature birth soon follows. Such fetuses
are usually found to be well nourished. Autopsy studies
have shown some adaptation to infectious stress as the
fetus can exhibit a granulopoietic response w13, 24x and
form bronchus-associated lymphoid tissue as a specific
reaction to AI w5x. PE, on the other hand, causes
prolonged fetal stress resulting in infants who appear
starved when eventually born prematurely after labor
induction or cesarean section performed for maternal
indications w14, 25, 26x.
The aim of the present study was to characterize and
compare 17-OHP levels in prematurity associated with AI
and PE, based on the hypothesis that 17-OHP levels
would be lower in the AI group.
Patients and methods
The study population comprised 90 premature infants born
between 25 and 33 weeks’ gestation (Table 1). Infants with mal-
formations or chromosomal abnormalities were not included. Of
the 37 AI infants, 20 were born between 1993 and 1999 and had
been included in a previous study w4x; the additional 17, who
met the same four diagnostic criteria (maternal fever, elevated
maternal C-reactive protein, fetal tachycardia, and chorioamnio-
nitis on placental histology), were born between January 2003
and November 2004. There were no changes in biochemical
analytical methods between periods. Similarly, of the 53 PE
infants, 25 were born between 1993 and 1999 and had been
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Table 1 Gestational age of 90 infants exposed to amniotic
infection or preeclampsia.
n Mean Median Range
Amniotic infection 37 28 5/7 28 3/7 25–33
Preeclampsia 53 29 4/7 29 6/7 24–33
Table 3 Thyroid-stimulating hormone (TSH) and 17-hydroxyprogesterone (17-OHP) in 90 infants exposed to amniotic infection or
preeclampsia.
TSH (mU/L blood) 17-OHP (nmol/L blood) 17-OHP )55 nmol/L blood
Mean Range Mean Range n %
Amniotic infection 12.7 2.3–43.4 54.6 21.5–164 16 43
Preeclampsia 10.0 1.3–28.4 85.7 26.1–293 39 74
Table 2 Stress indicators: Mean umbilical artery pH, base
excess and 1-min Apgar score in 90 premature infants exposed
to amniotic infection or preeclampsia.
pH Base excess Apgar
Amniotic infection 7.31 y2.8 5
Preeclampsia 7.27 y2.2 5
included in the previous study w4x; the additional 28, whose
mothers met the same diagnostic criteria (proteinuria )300
mg/d, and diastolic blood pressure )90 mm Hg on two occa-
sions at least 4 h apart, after week 20 of gestation and regress-
ing after delivery) w19x, were born between January 2003 and
November 2004. Intrauterine growth restriction (IUGR) was sus-
pected when estimated fetal weight was below the 5th percentile
of the reference chart in combination with either pathological
umbilical artery Doppler blood flow or a diminished amount of
amniotic fluid. However, for this study only actual birth weight
-10th percentile was used (ns20, all in the PE group). Infants
with AI were born either by cesarean section (25 infants) or
spontaneously (12 infants), whereas infants from the PE group
were all born by cesarean section. Antenatal steroids were given
to the 33 of 53 infants from the PE group and 34 of 37 infants
with AI.
In order to control for acute stress, the umbilical arterial cord
blood gas analysis and the 1-min Apgar score of all premature
infants were evaluated and compared (Table 2).
Blood was collected onto filter paper (dried blood spots wDBSx
technique) in the first three hours of life from the umbilical artery
catheter placed in all infants weighing -1000 g or with actual
or imminent respiratory decompensation. 17-OHP levels were
measured with a solid-phase competitive fluoroimmunoassay
using europium (Eu) labeled 17-OHP as tracer (Delfia neonatal
17-OHP kit, Wallac, Turku, Finland). DBS disks three millimeters
in diameter were punched into microtiter plate wells coated with
anti-mouse IgG. Assay buffer and 17-OHP antibody were added
to the wells and incubated under shaking for one hour; Eu-
labeled 17-OHP was then added, followed by incubation for two
more hours under shaking. After washing to remove non-reacted
components, Eu fluorescence was read with a time-resolved
fluorometer, and 17-OHP results expressed as nmol/L blood. All
assays were performed in duplicate. Thyroid-stimulating hor-
mone (TSH) was measured using a sandwich fluoroimmuno-
assay (Delfia). Punched three millimeter DBS disks were
incubated with buffer and Eu-labeled TSH in microtiter plates for
four hours under shaking. Fluorescence was measured after
washing and TSH results expressed as mU/L blood.
The Mann-Whitney non-parametric test was used to compare
unpaired groups followed by a x2 test for nominal data at the
5% significance level.
Results
Acute stress parameters – umbilical artery pH, base
excess and 1-min Apgar score – did not differ signifi-
cantly between the groups (Table 2). Birth weight, a
chronic intrauterine stress parameter, was lower in infants
from the PE group (P-0.01). 17-OHP levels were unre-
lated to gestational age within the range of our popula-
tion (25–33 weeks). The intergroup difference in mean
17-OHP levels was highly significant: 54.6 nmol/L in the
AI vs. 85.7 nmol/L in the PE group (P-0.001), and was
even more striking – 54.6 nmol/L vs. 99.8 nmol/L – if
intrauterine growth restriction (birth weight-10th percen-
tile: ns20, all in the PE group) was present. In addition,
values above the 50th percentile of the normal value for
premature infants (55 nmol/L blood) w28x were more fre-
quent in the PE group (74% vs. 43%, Table 3), indicating
that the ‘‘normal’’ range is skewed by the inclusion of
pathological conditions of infants at birth. In contrast to
17-OHP, TSH levels (AI: 12.7 mU/L; PE: 10.0 mU/L; PEq
birth weight -10th percentile: 10.9 mU/L blood) did not
differ significantly between the groups (Table 3).
Antenatal steroids did not significantly affect 17-OHP
(in the AI group: mean value with antenatal steroids was
55 nmol/L compared to 47 nmol/L in cases without ster-
oids, Ps0.63; in the PE group: mean value with antenatal
steroids was 76 nmol/L compared to 92 nmol/L in cases
without steroids, Ps0.10). Regarding mode of delivery,
AI only could be studied. 17-OHP was not significantly
different between subgroups (mean value after cesarean
56 nmol/L vs. mean value after spontaneous delivery
50 nmol/L).
Discussion
Neonatal screening comprises, among others, 17-OHP
and TSH assessment w3, 11, 16, 18, 21, 28x. Low serum
TSH values have been reported in prematurity associated
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with PE or placental insufficiency w7x. Our sample con-
firmed lower TSH values in the PE group but the differ-
ence was not significant. In contrast, the difference in
17-OHP levels between AI and PE infants was highly sig-
nificant, with levels being even more increased in growth-
restricted infants from the PE group. In accordance with
Gatelais et al. w8x this was not influenced by a single
course of antenatal steroids.
We draw the following conclusions: (i) raised 17-OHP
levels can be used as a marker of chronic intrauterine
stress, in contrast to cortisol which is increased under a
variety of conditions w2, 6, 9, 15, 22x; (ii) the wide variance
in ‘‘normal’’ prematurity 17-OHP is most probably due to
the failure, when setting the normal range, to exclude
growth-restricted infants of PE pregnancies, a common
prematurity subgroup w3, 11, 16, 18, 21, 28x; our data
indicate that normal 17-OHP levels need to be redefined
given that maternal PE accounts for about 30% of all
preterm infants, not only in our sample but also in others
w23, 27x; (iii) high 17-OHP levels in individual infants sig-
nify greater risk and earlier requirement for intensive care
w1, 4, 12, 17, 20, 29–31x.
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